Unibest

Pharmaceutical intermediates

Dacomitinib Intermediates

1 pharmaceutical intermediate for Dacomitinib. Indication: Carcinoma, Non-Small-Cell Lung.

Submit a ProjectAll intermediates

About Dacomitinib

Originator
Pfizer Inc
Indication
Carcinoma, Non-Small-Cell Lung
Approved Date
09/27/2018
DS/DP
05/05/2025

Available intermediates

1 intermediate currently listed for Dacomitinib. Request specifications, documentation or a quotation for any item below.

Dacomitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(2E)-4-(1-Piperidinyl)-2-butenoic acid hydrochloride197892-69-6//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDanicopanDapagliflozinDaridorexant HydrochlorideDarolutamideDasatinib Hydrate

Building toward Dacomitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →